MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41417-023-00720-0

Медицинская библиотека · Cancer gene therapy · 2023

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.

Conley Anthony P, Roland Christina L, Bessudo Alberto, Gastman Brian R, Villaflor Victoria M, Larson Christopher, Reid Tony R, Caroen Scott, Oronsky Bryan, Stirn Meaghan, Williams Jeannie, Burbano Erica, Coyle Angelique, Barve Minal A, Wagle Naveed, Abrouk Nacer, Kesari Santosh

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод требует повторной обработки

Аннотация

AdAPT-001 is an oncolytic adenovirus (OAV) with a transforming growth factor beta (TGF-ß) trap, which neutralizes the immunosuppressive and profibrotic cytokine, TGF-ß. The aim or purpose of this phase 1 study was to assess the safety and tolerability and, secondarily, the efficacy of AdAPT-001 after single intratumoral injection (IT) (Part 1) and multidose IT injection (Part 2) in patients with superficially accessible, advanced refractory solid tumors. Part 1 enrolled 9 patients with a 3 + 3 single dose-escalation safety run-in involving 2.5 × 1011, 5.0 × 1011, 1.0 × 1012 viral particles (vps). No dose-limiting toxicities or treatment-related serious adverse events (SAEs) were seen. In Part 2, a dose-expansion phase, 19 patients received AdAPT-001 at 1.0 × 1012 vps until disease progression according to Response Evaluation Criteria in Solid Tumors or RECIST 1.1. The overall responses to treatment included confirmed partial responses (3), durable stable disease ≥ 6 months (5), and progressive disease (13). AdAPT-001 is well tolerated. Evidence of an anti-tumor effect was seen in both injected and uninjected lesions. The recommended Phase 2 dose was 1.0 × 1012 vp administered by intratumoral injection once every 2 weeks. Combination of AdAPT-001 with a checkpoint inhibition is enrolling.

Для цитирования: Conley Anthony P, Roland Christina L, Bessudo Alberto, Gastman Brian R, Villaflor Victoria M, Larson Christopher, Reid Tony R, Caroen Scott, Oronsky Bryan, Stirn Meaghan, Williams Jeannie, Burbano Erica, Coyle Angelique, Barve Minal A, Wagle Naveed, Abrouk Nacer, Kesari Santosh. BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.. Cancer gene therapy. 2023. DOI: 10.1038/s41417-023-00720-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.